{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T22:17:31Z","timestamp":1791152251647,"version":"4.1.0"},"reference-count":23,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2009,5,6]],"date-time":"2009-05-06T00:00:00Z","timestamp":1241568000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2009,9]]},"abstract":"<jats:p><jats:bold>Objectives\n\t\t\t\t\t<\/jats:bold> The aims of the study were to describe the clinical presentation and renal and bone abnormalities in a case series of HIV\u2010infected patients receiving treatment with tenofovir (TDF), and to recommend appropriate screening for toxicity related to TDF.<\/jats:p><jats:p><jats:bold>Methods\n\t\t\t\t\t<\/jats:bold> Patients were identified from referrals to a specialist HIV renal clinic. Patients were included if treatment with TDF was assessed as the primary cause of the renal function impairment and clinical data were available prior to and following discontinuation of TDF treatment. Data were collected from case note review and clinic databases.<\/jats:p><jats:p><jats:bold>Results\n\t\t\t\t\t<\/jats:bold> Twenty\u2010two patients (1.6% of all those who received TDF) were identified with TDF\u2010associated renal toxicity. All had normal serum creatinine prior to TDF therapy. All presented with proteinuria. On stopping TDF, renal function improved. Eight patients had confirmed Fanconi syndrome. Twelve patients presented with bone pain and osteomalacia was confirmed on an isotope bone scan in seven of these patients. The findings (in those patients tested) of tubular proteinuria, reduced tubular transport maximum of phosphate (TmP), and glycosuria were all consistent with the proximal tubule being the site of toxicity.<\/jats:p><jats:p><jats:bold>Conclusion\n\t\t\t\t\t<\/jats:bold> Renal toxicity remains a concern in patients treated with TDF. Clinical presentation may be with renal dysfunction, Fanconi syndrome or osteomalacia. Our investigations suggest proximal tubular toxicity as a common pathogenic mechanism.<\/jats:p>","DOI":"10.1111\/j.1468-1293.2009.00716.x","type":"journal-article","created":{"date-parts":[[2009,5,7]],"date-time":"2009-05-07T02:43:37Z","timestamp":1241664217000},"page":"482-487","source":"Crossref","is-referenced-by-count":236,"title":["Tenofovir\u2010associated renal and bone toxicity"],"prefix":"10.1111","volume":"10","author":[{"given":"CLN","family":"Woodward","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AM","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"IG","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Madge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Copas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SG","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MA","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JO","family":"Connolly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,8,2]]},"reference":[{"key":"e_1_2_5_2_2","first-page":"535","article-title":"Tenofovir disoproxil fumarate, emtricitabine, and efavirenz vs. fixed\u2010dose zidovudine\/lamivudine and efavirenz in antiretroviral\u2010na\u00efve patients","volume":"43","author":"Pozniak AL","year":"2006","journal-title":"virologic, immunologic, and morphologic changes \u2013 a 96-week analysis"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh658"},{"key":"e_1_2_5_4_2","first-page":"570","article-title":"Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse\u2010transcriptase inhibitor treatment","volume":"41","author":"Gallant JE","year":"2005","journal-title":"Clin Infect Dis"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2006.00349.x"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.5.1469-1487.2004"},{"key":"e_1_2_5_7_2","first-page":"269","article-title":"Renal tubular dysfunction associated with tenofovir therapy","volume":"35","author":"Peyriere H","year":"2004","journal-title":"report of 7 cases"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200404300-00019"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2005.00318.x"},{"key":"e_1_2_5_10_2","first-page":"155A","article-title":"A simplified equation to predict glomerular filtration rate from serum creatinine","volume":"11","author":"Levey AS","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198312223092503"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1797.2006.00564.x"},{"key":"e_1_2_5_13_2","first-page":"504","article-title":"Cross sectional longitudinal study of spot morning urine protein","volume":"316","author":"Ruggenenti P","year":"1998","journal-title":"creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200501030-00012"},{"key":"e_1_2_5_15_2","first-page":"191","article-title":"903 Study Group. Efficacy and safety of tenofovir DF vs. stavudine in combination therapy in antiretroviral\u2010na\u00efve patients","volume":"292","author":"Gallant JE","year":"2004","journal-title":"a 3-year randomized trial"},{"key":"e_1_2_5_16_2","first-page":"2165","article-title":"Antiretroviral therapy and the prevalence of osteopenia and osteoporosis","volume":"20","author":"Brown TT","year":"2006","journal-title":"a meta-analytic review"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2005.07.020"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2001.00016.x"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(96)90517-X"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-3542(03)00005-6"},{"key":"e_1_2_5_21_2","first-page":"716","article-title":"Assessment of mitochondrial toxicity in human cells treated with tenofovir","volume":"46","author":"Birkus G","year":"2002","journal-title":"comparison with other nucleoside reverse transcriptase inhibitors"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000243103.03265.2b"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00251-06"},{"key":"e_1_2_5_24_2","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/135965350701200211","article-title":"Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors","volume":"12","author":"Cihlar T","year":"2007","journal-title":"Antivir Ther"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2009.00716.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1293.2009.00716.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T16:19:38Z","timestamp":1696868378000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2009.00716.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8,2]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["10.1111\/j.1468-1293.2009.00716.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2009.00716.x","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,8,2]]}}}